These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 14671507)

  • 21. Clinical outcomes of first antiretroviral regimen in HIV/hepatitis C virus co-infection.
    Cooper CL; Breau C; Laroche A; Lee C; Garber G
    HIV Med; 2006 Jan; 7(1):32-7. PubMed ID: 16313290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Livolin ameliorates elevations in alanine transaminase in HIV infected patients commencing highly active antiretroviral therapy.
    Otegbayo JA; Kuti MA; Ogunbode O; Irabor AE; Adewoles IF
    Afr J Med Med Sci; 2012 Dec; 41(4):417-22. PubMed ID: 23672107
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001.
    Law WP; Dore GJ; Duncombe CJ; Mahanontharit A; Boyd MA; Ruxrungtham K; Lange JM; Phanuphak P; Cooper DA
    AIDS; 2003 Oct; 17(15):2191-9. PubMed ID: 14523276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NNRTI hepatotoxicity: efavirenz versus nevirapine.
    Pulido F; Torralba M
    J HIV Ther; 2002 Nov; 7 Suppl 2():S3-16. PubMed ID: 12735215
    [No Abstract]   [Full Text] [Related]  

  • 25. Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus.
    Cooper CL; Parbhakar MA; Angel JB
    Clin Infect Dis; 2002 May; 34(9):1259-63. PubMed ID: 11941553
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients.
    Stern JO; Robinson PA; Love J; Lanes S; Imperiale MS; Mayers DL
    J Acquir Immune Defic Syndr; 2003 Sep; 34 Suppl 1():S21-33. PubMed ID: 14562855
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatotoxicity in patients prescribed efavirenz or nevirapine.
    Brück S; Witte S; Brust J; Schuster D; Mosthaf F; Procaccianti M; Rump JA; Klinker H; Petzold D; Hartmann M
    Eur J Med Res; 2008 Jul; 13(7):343-8. PubMed ID: 18700192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting.
    Kalyesubula R; Kagimu M; Opio KC; Kiguba R; Semitala CF; Schlech WF; Katabira ET
    Afr Health Sci; 2011 Mar; 11(1):16-23. PubMed ID: 21572852
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liver injury in HIV-1-infected patients receiving non-nucleosides reverse transcriptase inhibitors-based antiretroviral therapy.
    Li ZC; Li HJ; Dai LL; Gao YQ; Cai WP; Li HY; Huang XJ; Zhang T; Wu H
    Chin Med J (Engl); 2010 Dec; 123(24):3587-90. PubMed ID: 22166636
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
    Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
    HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiretroviral hepatotoxicity in human immunodeficiency virus-infected patients.
    Hernandez LV; Gilson I; Jacobson J; Affi A; Puetz TR; Dindzans VJ
    Aliment Pharmacol Ther; 2001 Oct; 15(10):1627-32. PubMed ID: 11564003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
    Neukam K; Mira JA; Ruiz-Morales J; Rivero A; Collado A; Torres-Cornejo A; Merino D; de Los Santos-Gil I; Macías J; González-Serrano M; Camacho A; Parra-García G; Pineda JA;
    J Antimicrob Chemother; 2011 Nov; 66(11):2605-14. PubMed ID: 21903660
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiretroviral drugs and liver injury.
    Soriano V; Puoti M; Garcia-Gascó P; Rockstroh JK; Benhamou Y; Barreiro P; McGovern B
    AIDS; 2008 Jan; 22(1):1-13. PubMed ID: 18090386
    [No Abstract]   [Full Text] [Related]  

  • 34. Risk factors for grade 3-4 liver enzyme elevation in HIV and hepatitis C coinfected patients on combination antiretroviral therapy.
    Chihrin S; Antoniou T; Raboud J; Shen S; Govan V; Fletcher D; Rachlis A; Kovacs C; Crouzat F; Tilley D; Chang B; Saskin R; Loutfy MR
    AIDS Patient Care STDS; 2007 Jul; 21(7):469-78. PubMed ID: 17651028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors.
    Dieterich DT; Robinson PA; Love J; Stern JO
    Clin Infect Dis; 2004 Mar; 38 Suppl 2():S80-9. PubMed ID: 14986279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liver enzymes improve over twenty-four months of first-line non-nucleoside reverse transcriptase inhibitor-based therapy in rural Uganda.
    Weidle PJ; Moore D; Mermin J; Buchacz K; Were W; Downing R; Kigozi A; Ndazima V; Peters P; Brooks JT
    AIDS Patient Care STDS; 2008 Oct; 22(10):787-95. PubMed ID: 18778241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Toxicity of non-nucleoside analogue reverse transcriptase inhibitors.
    Kontorinis N; Dieterich DT
    Semin Liver Dis; 2003 May; 23(2):173-82. PubMed ID: 12800070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection.
    Aceti A; Pasquazzi C; Zechini B; De Bac C;
    J Acquir Immune Defic Syndr; 2002 Jan; 29(1):41-8. PubMed ID: 11782588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The interaction of CD4 T-cell count and nevirapine hepatotoxicity in China: a change in national treatment guidelines may be warranted.
    Zhang C; Wang W; Zhou M; Han Y; Xie J; Qiu Z; Guo F; Li Y; Wang H; Ghanem KG; Li T
    J Acquir Immune Defic Syndr; 2013 Apr; 62(5):540-5. PubMed ID: 23288032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients.
    Labarga P; Soriano V; Vispo ME; Pinilla J; Martin-Carbonero L; Castellares C; Casado R; Maida I; Garcia-Gasco P; Barreiro P
    J Infect Dis; 2007 Sep; 196(5):670-6. PubMed ID: 17674307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.